Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $18.00 | Buy | H.C. Wainwright |
| 7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024: The Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024. A corporate presentation is scheduled for 9:45 a.m. Eastern Time. The Jefferies 2024 London Healthcare Conference on Thursday, November 21, 2024. A fireside chat is scheduled for 11:30 a.m. Greenwich Mean Time (6:30 a.m. Eastern Time). The corporate presentation and fireside chat given at the Stifel and Je
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash rangesFanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023Fanapt® long acting injectable program expected to be initiated in Q4 2024Milsaperidone NDA for schizophrenia and bipolar I disorder expected to be submitted in early 2025; initiation of major depressive disorder program expected in Q4 2024PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024PONVORY® IND applications for psoriasis and ulcerative colitis expected to be submitted in Q4 2024Tradipi
Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2555000. The
H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00
Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously
10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Vanda Pharma (NASDAQ:VNDA) with a Overweight rating and announces Price Target of $11.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading lower after Future Pak withdrew its proposal to purchase the company. “Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals, Future Pak LLC and its affiliates today announced that it is withdrawing its offer to acquire the company, effective immediately, and will focus on other strategic objectives,” according to a statement. This decision follows Vanda’s ongoing lack of response and their rejection of Future Pak’s final proposal. According to Benzinga Pro, VNDA stock has lost over 9% in the past year. Investors can gain exposure to the stock via Invesco NASDAQ Future Gen 200 ETF (NASD
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash rangesFanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023Fanapt® long acting injectable program expected to be initiated in Q4 2024Milsaperidone NDA for schizophrenia and bipolar I disorder expected to be submitted in early 2025; initiation of major depressive disorder program expected in Q4 2024PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024PONVORY® IND applications for psoriasis and ulcerative colitis expected to be submitted in Q4 2024Tradipi
Conference Call and Webcast to Follow WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2555000. The
Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023Financial Guidance reinstated for Full Year 2024Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 18, 2024Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024WASHINGTON, July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational res
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin